Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
Latest news
Date Title
22m ago OLYMPUS : Federal Contracts Awarded by Federal Agencies in Indiana (Oct. 25)
23m ago HONEYWELL : Federal Contracts Awarded by Federal Agencies in Alabama (Oct. 25)
23m ago HONEYWELL : Federal Contracts Awarded to Companies in Arizona (Oct. 25)
23m ago CONCURRENT TECHNOLOGIES : Federal Contracts Awarded to Companies in Pennsylvania (Oct. 25)
23m ago CONCURRENT TECHNOLOGIES : Federal Contracts Awarded by Federal Agencies in Pennsylvania (Oct. 25)
48m ago SYNGENTA : Triton Algae Innovations Ltd. Names Dr. Xun Wang as President
57m ago FORTINET : Unveils Industry's First Multi-Gigabit Next Generation Firewall in the Middle East; Protects Mid-Enterprises with 5 Times the Performance
57m ago AUTODESK : and Local Motors Collaborate on First Spark 3D Platform Implementation
57m ago MICHELIN : Gourmet gateway: expanded speciality food festival caters to growing regional appetite for fine foods
57m ago DUBAI FINANCIAL MARKET PJSC : Al Ramz Capital's Mobile Trade App recognized by Dubai Financial Market at GITEX 2014
Latest news
Advertisement
Hot News 
DIGITAL RIVER : Announces Agreement to be Acquired by Investor Group Led by Siris Capital Group for $26.00 per Share in Cash
EDREAMS ODIGEO : Statement responding to BA and Iberia statement
4IMPRINT : Full Year Expectations Underpinned By Strong Third Quarter
ATLANTIS RESOURCES : Raises GBP5.0 Million In Discounted Placing (ALLISS)
MERIT MEDICAL SYSTEMS : posts 3Q profit
Most Read News
1d ago MATSON : Shipping company pleads guilty in molasses spill
1d ago HEARTLAND EXPRESS : 2014 Q3 Earnings Release
1d ago APPLE : Time for all Apple products to enter China
13h ago PFIZER : Reports Vaccine Candidate Data
2h ago Deutsche Bank lawyer found dead by suicide in New York
Most recommended articles
2h ago Deutsche Bank lawyer found dead by suicide in New York
4h agoDJTHYSSENKRUPP : Denies in Talks to Sell Marine Systems to Rheinmetall
8h ago Russian government approves law to clamp down on offshore tax sheltering
8h ago Greybull Capital buys UK's Monarch
10h ago Areva-Siemens raises claim to $4.4 billion over Finnish reactor delays
Dynamic quotes  
ON
| OFF